Compare Coinbase Global, Inc. (COIN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs GeneDx Holdings Corp — how do they compare? Coinbase Global, Inc. trades at $179.9 (market cap $45.38B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Coinbase Global, Inc. is far larger — about 22.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 11,013,940). Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and GeneDx Holdings Corp for 19 Days on average.
| COIN | WGS | |
|---|---|---|
Market Cap | $45.38B | $2.02B |
Volume | 11,013,940 | 734,640 |
Sector | Financials | Health |
52-Week High | $387.00 | $167.51 |
52-Week Low | $141.09 | $34.51 |
Typical Hold Time | 78 Days | 19 Days |
Enterprise Value | $43.03B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $181.09, up 1.48% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported $7.18B revenue in 2025 with $1.26B net income, though recent quarterly earnings have missed expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, while analyst consensus remains bullish with a $211.91 price target.
The stock presents growth potential from expanding derivatives business and institutional partnerships, but faces risks from earnings volatility and crypto market exposure. With 55% analyst buy ratings and strong cash flow generation, COIN offers upside to price targets, though investors should monitor execution on profitability goals amid competitive pressures.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
